Keyphrases
Resistance Mechanisms
50%
Triple-negative Breast Cancer
50%
Cell-based
50%
Chimeric Antigen Receptor T Cells (CAR-T)
50%
Immunotherapeutic Strategy
37%
Therapy Types
37%
Triple-negative Breast Cancer Cells
25%
Metastatic Triple-negative Breast Cancer
25%
Clinical Setting
25%
Escape Mechanism
25%
T Cells
18%
Antitumor Activity
18%
T Cell Immunotherapy
12%
Tumor Antigen
12%
Young African American Women
12%
Breast Cancer
12%
Patient Mortality
12%
Solid Tumors
6%
Leukemia
6%
Chemotherapy
6%
Clinical Grade
6%
Host Immune Response
6%
Oncologists
6%
Phase I Clinical Trial
6%
Targeted Therapy
6%
Recurrent Disease
6%
Animal Model System
6%
Grant Proposal
6%
Metastasis
6%
Antigen-specific
6%
Genetic Engineering
6%
Novel Therapeutics
6%
Hypoxia
6%
Solid Tumor Therapy
6%
Targeted Treatment
6%
Collaborative Programs
6%
Tumor Cells
6%
Immune System
6%
Therapeutic Efficacy
6%
Effective Therapy
6%
Rational Design
6%
Tumor Microenvironment
6%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Triple Negative Breast Cancer
100%
Neoplasm
26%
Solid Malignant Neoplasm
13%
Tumor Antigen
13%
Breast Cancer
13%
Side Effect
6%
Hypoxia
6%
Clinical Trial
6%
Tumor Microenvironment
6%
Chimeric Antigen Receptor
6%
Combination Therapy
6%
Leukemia
6%
Chemotherapy
6%
Recurrent Disease
6%
Medicine and Dentistry
Immunotherapy
50%
Chimeric Antigen Receptor T-Cell
50%
Triple Negative Breast Cancer
50%
Cancer Cell
13%
T Cell
10%
Antineoplastic Activity
10%
Clinical Finding
6%
Targeted Therapy
6%
Breast Cancer
6%
Solid Malignant Neoplasm
6%
Immune System
6%
Tumor Antigen
6%